

Rafael S Rios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/344886/publications.pdf>

Version: 2024-02-01

22
papers

740
citations

1170033

9
h-index

843174

20
g-index

23
all docs

23
docs citations

23
times ranked

1240
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	0.7	4
2	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2022, 127, 1613-1620.	1.2	8
3	Interaction of <i>SAMM50-rs738491</i> , <i>PARVB-rs5764455</i> and <i>PNPLA3-rs738409</i> Increases Susceptibility to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 219-229.	0.7	3
4	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	4.5	6
5	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1259-1265.	1.1	6
6	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
7	<i>FNDC5</i> polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2021, 126, 813-824.	1.2	11
8	MAFLD and risk of CKD. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154433.	1.5	178
9	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	5
10	Recommendations and Clinical Guidance for Children with Metabolic-associated Liver Disease during the COVID-19 Pandemic. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	2
11	Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 811-819.	1.4	3
12	TA allele of rs2070673 in the <i>CYP2E1</i> gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2925-2934.	1.4	6
13	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 593-603.	1.4	19
14	Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis. , 2021, 32, 758-764.		0
15	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 430-435.	0.8	12
16	Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2911-2921.	0.9	21
17	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	1.4	27
18	COVID-19 Cross-Infection and Pressured Ulceration Among Healthcare Workers: Are We Really Protected by Respirators?. <i>Frontiers in Medicine</i> , 2020, 7, 571493.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. Chinese Medical Journal, 2020, 133, 2743-2745.	0.9	7
20	Data sharing during COVID-19 pandemic: what to take away. Expert Review of Gastroenterology and Hepatology, 2020, 14, 1125-1130.	1.4	20
21	Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2041-2050.	1.4	67
22	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	0.7	329